摘要
2型糖尿病患者骨折风险升高，因此在降糖治疗的同时关注降糖药物对骨骼的影响具有重要意义。研究发现，胰高血糖素样肽-1（GLP-1）类药物不仅能够控制血糖，还能通过调节成骨细胞Wnt通路、促进骨髓间充质干细胞向成骨细胞分化、影响破骨细胞核因子-κB受体活化因子配体通路、抑制骨细胞分泌骨硬化蛋白以及其他途径改善骨代谢，提示这类药物对2型糖尿病患者骨质疏松的防治有重要作用。
The risk of fractures in patients with type 2 diabetes is increased, therefore, it is impor- tant to take into account the effects of anti-diabetic therapies on bone. Studies show that glucagon-like pep- tide-1 （ GLP-1 ） -based therapies not only can lower blood glucose, but also improve bone metabolism by regu- lating Wnt pathways in osteoblast, promoting osteogenic differentiation of bone marrow mesenchymal stem cell （BMSC） , regulating receptor activator of nuclear factor KB ligand pathways in osteoclast, inhibiting scleros- tin secretion of osteocyte, etc. It suggests that GLP-1-based therapies play an essential role in the prevention and treatment of osteoporosis in patients with type 2 diabetes.
作者
阮莹莹
闫彩凤
Ruan Yingying;Yan Caifeng(Graduate School, Dalian Medical University, Dalian 116044, China;Department of Endocrinology, Subei People＇s Hos- pital of Jiangsu Province, Yangzhou 225001, China)
出处
《国际内分泌代谢杂志》
2018年第4期275-278,共4页
International Journal of Endocrinology and Metabolism
基金
扬州市社会发展基金（YZ2016061）
关键词
胰高血糖素样肽-1
2型糖尿病
骨形成
骨吸收
骨折
Glucagon-like peptide-1
Type 2 diabetes mellitus
Bone formation
Bone resorption
Fracture
